{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:15:11Z","timestamp":1740147311302,"version":"3.37.3"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) remains controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>We investigated the relationship between DAPT duration following PCI and long-term ischemic and bleeding outcomes under real-world conditions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients aged\u2009\u2265\u200965\u00a0years who underwent PCI with stenting in Western Australian hospitals between 2003 and 2008 and survived 2\u00a0years were identified from linked hospital admissions data. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of all-cause death and admissions for acute coronary syndrome (ACS), coronary artery revascularization procedure, stroke, and major bleeding. Secondary outcomes were ACS admissions, all-cause death, and major bleeding admissions. Patients were followed up for 5\u00a0years from initial PCI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 3963 patients were included in the final analysis. The mean age of the cohort was 74.5\u2009\u00b1\u20096.1\u00a0years with 67.3% males. No significant difference was seen with 6\u201312, 12\u201318, or 18\u201324\u00a0months DAPT, compared to 0\u20136\u00a0months DAPT duration for MACCE and all secondary outcomes at 3- and 5-year post-PCI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>There is no significant difference in both bleeding and ischemic outcomes in long-term DAPT as compared to short-term DAPT for first- and second-generation drug-eluting stents in a real-world population.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11845-022-03171-y","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T13:25:46Z","timestamp":1664457946000},"page":"1645-1647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-term DAPT after coronary stenting has similar ischemic and bleeding outcomes as long-term DAPT: a 5-year population-based cohort study"],"prefix":"10.1007","volume":"192","author":[{"given":"Sriraag","family":"Balaji Srinivasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amro","family":"Sehly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biyanka","family":"Jaltotage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Rahman","family":"Ihdayhid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Marangou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank M.","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-740X","authenticated-orcid":false,"given":"Girish","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"3171_CR1","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155\u20132166. https:\/\/doi.org\/10.1056\/NEJMoa1409312","journal-title":"N Engl J Med"},{"key":"3171_CR2","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791\u20131800. https:\/\/doi.org\/10.1056\/NEJMoa1500857","journal-title":"N Engl J Med"},{"key":"3171_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jjcc.2018.03.001","volume":"72","author":"LM Lugo","year":"2018","unstructured":"Lugo LM, Ferreiro JL (2018) Dual antiplatelet therapy after coronary stent implantation: individualizing the optimal duration. J Cardiol 72:94\u2013104. https:\/\/doi.org\/10.1016\/j.jjcc.2018.03.001","journal-title":"J Cardiol"},{"key":"3171_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","volume":"65","author":"M Gilard","year":"2015","unstructured":"Gilard M, Barragan P, Noryani AAL et al (2015) 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 65:777\u2013786. https:\/\/doi.org\/10.1016\/j.jacc.2014.11.008","journal-title":"J Am Coll Cardiol"},{"key":"3171_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001707","volume":"8","author":"A Bularga","year":"2021","unstructured":"Bularga A, Meah MN, Doudesis D et al (2021) Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. Open Heart 8:e001707. https:\/\/doi.org\/10.1136\/openhrt-2021-001707","journal-title":"Open Heart"},{"key":"3171_CR6","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.118.034456","volume":"138","author":"S Bangalore","year":"2018","unstructured":"Bangalore S, Toklu B, Patel N et al (2018) Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease. Circulation 138:2216\u20132226. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034456","journal-title":"Circulation"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03171-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03171-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03171-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T10:19:27Z","timestamp":1690798767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03171-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3171"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03171-y","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"17 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the University of Western Australia Human Research Ethics Committee (UWA HREC RA\/4\/1\/8065) and Western Australia Department of Health Human Research Ethics Committee (RGS2803), and the study was conducted according to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"BJ consults for the Artrya Pty Ltd. ARI consults and has equity interest in the Artrya Pty Ltd. GD received speaker bureau fees for Pfizer, Johnson and Johnson, and Amgen and conference sponsorship from Bayer and consults and has equity interest in the Artrya Pty Ltd. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}